Literature DB >> 19367504

Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.

Ziva D Cooper1, Margaret Haney.   

Abstract

Cannabis use disorders have been recently identified as a relevant clinical issue: a subset of cannabis smokers seeks treatment for their cannabis use, yet few succeed in maintaining long-term abstinence. The rewarding and positive reinforcing effects of the primary psychoactive component of smoked cannabis, delta-9-tetrahydrocannabinol (THC) are mediated by the cannabinoid CB1 receptor. The CB1 receptor has also been shown to mediate cannabinoid dependence and expression of withdrawal upon cessation of drug administration, a phenomenon verified across species. This paper will review findings implicating the CB1 receptor in the behavioural effects of exogenous cannabinoids with a focus on cannabinoid dependence and reinforcement, factors that contribute to the maintenance of chronic cannabis smoking despite negative consequences. Opioidergic modulation of these effects is also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19367504      PMCID: PMC2731700          DOI: 10.1080/09540260902782752

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  100 in total

1.  Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

2.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.

Authors:  A J Budney; P L Novy; J R Hughes
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

3.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice.

Authors:  E Valjent; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

Review 5.  Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.

Authors:  Margaret Haney
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

6.  Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

7.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

8.  A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

Authors:  Jenny L Wiley; Kari L LaVecchia; Natalie E Karp; Sanjitha Kulasegram; Anu Mahadevan; Raj K Razdan; Billy R Martin
Journal:  Exp Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.157

9.  Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.

Authors:  Zuzana Justinova; Patrik Munzar; Leigh V Panlilio; Sevil Yasar; Godfrey H Redhi; Gianluigi Tanda; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

10.  Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.

Authors:  R S Mansbach; C C Rovetti; E N Winston; J A Lowe
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

View more
  29 in total

Review 1.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  The potential impact of cannabis legalization on the development of cannabis use disorders.

Authors:  Alan J Budney; Jacob T Borodovsky
Journal:  Prev Med       Date:  2017-06-28       Impact factor: 4.018

Review 3.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

4.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

Review 5.  Cannabinoid abuse and addiction: Clinical and preclinical findings.

Authors:  L V Panlilio; S R Goldberg; Z Justinova
Journal:  Clin Pharmacol Ther       Date:  2015-05-02       Impact factor: 6.875

Review 6.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

7.  Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers.

Authors:  J Hirvonen; R S Goodwin; C-T Li; G E Terry; S S Zoghbi; C Morse; V W Pike; N D Volkow; M A Huestis; R B Innis
Journal:  Mol Psychiatry       Date:  2011-07-12       Impact factor: 15.992

8.  Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer 'Medicalized' Programs.

Authors:  Arthur Robin Williams; Mark Olfson; June H Kim; Silvia S Martins; Herbert D Kleber
Journal:  Health Aff (Millwood)       Date:  2016-03       Impact factor: 6.301

9.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

10.  Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.

Authors:  Ziva D Cooper; Sandra D Comer; Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2013-04-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.